# A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation

> **NCT00787150** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 222 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Apixaban
- **DRUG:** Apixaban
- **DRUG:** Warfarin sodium

## Key facts

- **NCT ID:** NCT00787150
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2013-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00787150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00787150, "A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00787150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*